Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

 Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

Shots:

  • The P-II EMPOWER CSCC-1 study results involve assessing of Libtayo (cemiplimab-rwlc) in patients with LA & metastatic CSCC and will be presented at ASCO 2019
  • The P-II EMPOWER CSCC-1 study results: median follow-up (9 & 17mos.); ORR (44% & 49%); CRR (13% & 17%); PRR (31% & 32%); DCR @≥16wks. (63% & 63%); mPFS with metastatic CSCC (18mos.)
  • Libtayo is a mAb targeting PD-1, co-developed by Regeneron and Sanofi utilizing VelocImmune technology and has received FDA’s approval for patients with metastatic CSCC or LA CSCC who are not candidates for curative surgery or curative radiation in Sep’18

Click here to read full press release/ article | Ref: Sanofi | Image: Etoile

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post